172 related articles for article (PubMed ID: 26341695)
21. Lu-177-Labeled Zirconia Particles for Radiation Synovectomy.
Polyak A; Nagy LN; Drotár E; Dabasi G; Jóba RP; Pöstényi Z; Mikolajczak R; Bóta A; Balogh L
Cancer Biother Radiopharm; 2015 Dec; 30(10):433-8. PubMed ID: 26683134
[TBL] [Abstract][Full Text] [Related]
22. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
23. Imaging DNA damage response by γH2AX
O'Neill E; Mosley M; Cornelissen B
Theranostics; 2023; 13(4):1302-1310. PubMed ID: 36923536
[No Abstract] [Full Text] [Related]
24. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
[TBL] [Abstract][Full Text] [Related]
26. (177)Lu-Labeled Cerasomes Encapsulating Indocyanine Green for Cancer Theranostics.
Jing L; Shi J; Fan D; Li Y; Liu R; Dai Z; Wang F; Tian J
ACS Appl Mater Interfaces; 2015 Oct; 7(39):22095-105. PubMed ID: 26398723
[TBL] [Abstract][Full Text] [Related]
27. Radiolabeling of benzylpenicillin with lutetium-177: Quality control and biodistribution study to develop theranostic infection imaging agent.
Shahzad MA; Naqvi SAR; Rasheed R; Yameen M; Anjum F; Ahmed MT; Hussain Z; Gillani SJH
Pak J Pharm Sci; 2017 Nov; 30(6(Supplementary)):2349-2354. PubMed ID: 29188768
[TBL] [Abstract][Full Text] [Related]
28. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
29. Science to practice: can theranostic fullerenes be used to treat brain tumors?
Bulte JW
Radiology; 2011 Oct; 261(1):1-2. PubMed ID: 21931135
[TBL] [Abstract][Full Text] [Related]
30. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
[TBL] [Abstract][Full Text] [Related]
31. Lipid-coated calcium phosphate nanoparticle and beyond: a versatile platform for drug delivery.
Huang JL; Chen HZ; Gao XL
J Drug Target; 2018; 26(5-6):398-406. PubMed ID: 29258343
[TBL] [Abstract][Full Text] [Related]
32. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
33. Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases.
Tseng YC; Xu Z; Guley K; Yuan H; Huang L
Biomaterials; 2014 May; 35(16):4688-98. PubMed ID: 24613050
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional Cyanine-Based Theranostic Probe for Cancer Imaging and Therapy.
Peng CL; Shih YH; Chiang PF; Chen CT; Chang MC
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830094
[TBL] [Abstract][Full Text] [Related]
35. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
36. Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
Yook S; Lu Y; Jeong JJ; Cai Z; Tong L; Alwarda R; Pignol JP; Winnik MA; Reilly RM
Biomacromolecules; 2016 Apr; 17(4):1292-302. PubMed ID: 26974228
[TBL] [Abstract][Full Text] [Related]
37. In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.
Chatalic KL; Konijnenberg M; Nonnekens J; de Blois E; Hoeben S; de Ridder C; Brunel L; Fehrentz JA; Martinez J; van Gent DC; Nock BA; Maina T; van Weerden WM; de Jong M
Theranostics; 2016; 6(1):104-17. PubMed ID: 26722377
[TBL] [Abstract][Full Text] [Related]
38. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Persson M; Juhl K; Rasmussen P; Brandt-Larsen M; Madsen J; Ploug M; Kjaer A
Mol Pharm; 2014 Aug; 11(8):2796-806. PubMed ID: 24955765
[TBL] [Abstract][Full Text] [Related]
39. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
[TBL] [Abstract][Full Text] [Related]
40. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer.
Fischer E; Grünberg J; Cohrs S; Hohn A; Waldner-Knogler K; Jeger S; Zimmermann K; Novak-Hofer I; Schibli R
Int J Cancer; 2012 Jun; 130(11):2715-21. PubMed ID: 21796623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
